Search results for "ulcer."

showing 10 items of 519 documents

Tofacitinib in Ulcerative Colitis: Real-world Evidence From the ENEIDA Registry.

2021

Abstract Aim To evaluate the effectiveness and safety of tofacitinib in ulcerative colitis [UC] in real life. Methods Patients from the prospectively maintained ENEIDA registry and treated with tofacitinib due to active UC were included. Clinical activity and effectiveness were defined based on Partial Mayo Score [PMS]. Short-term response/remission was assessed at Weeks 4, 8, and 16. Results A total of 113 patients were included. They were exposed to tofacitinib for a median time of 44 weeks. Response and remission at Week 8 were 60% and 31%, respectively. In multivariate analysis, higher PMS at Week 4 (odds ratio [OR] = 0].2; 95% confidence interval [CI] = 0].1–0.4) was the only variable …

Malemedicine.medical_specialtyPiperidinesRecurrenceInternal medicinemedicineHumansRegistriesAdverse effectProtein Kinase Inhibitorsulcerative colitisTofacitinibDose-Response Relationship Drugbusiness.industryTtofacitinib ulcerative colitisRemission InductionHazard ratioPatient AcuityGastroenterologyGeneral MedicineOdds ratioMiddle Agedmedicine.diseaseUlcerative colitisConfidence intervaldigestive system diseasesDiscontinuationPyrimidinesTreatment OutcomeSpainCohortColitis UlcerativeFemaleDrug MonitoringbusinessTtofacitinib
researchProduct

Pressure ulcers’ incidence, preventive measures, and risk factors in neonatal intensive care and intermediate care units

2018

Epidemiological studies on pressure ulcers (PUs) in hospitalised infants are scarce. Spain lacks comprehensive research studies providing data on the prevalence or incidence in this population. This work was developed to determine the incidence of PUs in hospitalised infants admitted to intensive and intermediate care units, along with relevant risk factors and preventive measures. A prospective study appraising the incidence of PUs in infants was performed. The risk factors and preventive measures were evaluated using a multivariate logistic regression model. A sample of 268 infants was included. The cumulative incidence of PUs was 12.70% (95% confidence interval, CI(95%) = [8.95%‐17.28%])…

Malemedicine.medical_specialtyPopulationIntermediate care unitDermatologyIntensive Care Units PediatricPressure ulcer030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineRisk FactorsIntensive careEpidemiologyPrevalencemedicineHumansCumulative incidenceProspective StudieseducationPressure UlcerKangaroo careeducation.field_of_studyIntensive care units030504 nursingbusiness.industryIncidenceIncidence (epidemiology)Infant NewbornInfantOriginal ArticlesLogistic ModelsRisk factorsSpainRelative riskEmergency medicineIntensive Care NeonatalFemaleEnfermeríaSurgery0305 other medical scienceRisk assessmentbusinessInternational Wound Journal
researchProduct

Gastric antisecretory drugs induce leukocyte-endothelial cell interactions through gastrin release and activation of CCK-2 receptors.

2007

Antisecretory drugs are effective antiulcer agents, but its chronic use generates hypergastrinemia and accelerates the development of atrophic gastritis in Helicobacter pylori-positive patients. We have recently shown that gastrin exerts a proinflammatory effect in rats through CCK-2 receptor activation that contributes to the inflammation induced by H. pylori. The present study was designed to examine whether gastrin hypersecretion in response to treatment with antisecretory drugs induces an inflammatory response that could promote mucosal atrophy. The effects of omeprazole or famotidine on leukocyte/endothelial cell interactions in vivo were analyzed in rat mesenteric venules using intrav…

Malemedicine.medical_specialtyProglumidemedicine.drug_classInflammationCD18Cell CommunicationProinflammatory cytokineRats Sprague-DawleyInternal medicineGastrinsmedicineLeukocytesAnimalsOmeprazoleGastrinPharmacologyInflammationMicroscopy Videobusiness.industryEndothelial CellsProton Pump InhibitorsReceptor antagonistAnti-Ulcer AgentsFlow CytometryImmunohistochemistryReceptor Cholecystokinin BRatsFamotidineChemotaxis LeukocyteEndocrinologyGastric MucosaMolecular Medicinemedicine.symptombusinessmedicine.drugThe Journal of pharmacology and experimental therapeutics
researchProduct

Arterial stiffness, endothelial and cognitive function in subjects with type 2 diabetes in accordance with absence or presence of diabetic foot syndr…

2017

BACKGROUND: Endothelial dysfunction is an early marker of cardiovascular disease so endothelial and arterial stiffness indexes are good indicators of vascular health. We aimed to assess whether the presence of diabetic foot is associated with arterial stiffness and endothelial function impairment. METHODS: We studied 50 subjects with type 2 diabetes mellitus and diabetic foot syndrome (DFS) compared to 50 diabetic subjects without diabetic foot, and 53 patients without diabetes mellitus, by means of the mini mental state examination (MMSE) administered to evaluate cognitive performance. Carotid-femoral pulse wave velocity (PWV) and augmentation index (Aix) were also evaluated by Applanation…

Malemedicine.medical_specialtySettore MED/09 - Medicina InternaEndocrinology Diabetes and Metabolism030209 endocrinology & metabolismType 2 diabetes030204 cardiovascular system & hematologyVascular stiffness03 medical and health sciencesCognition0302 clinical medicineEndothelium functionDiabetes mellitusInternal medicineHumansMedicineEndothelial dysfunctionReactive hyperemiaPulse wave velocityAgedOriginal InvestigationFoot ulcerVascular healthbusiness.industryType 2 Diabetes MellitusMiddle Agedmedicine.diseaseDiabetic footDiabetic FootSurgeryCross-Sectional StudiesDiabetes Mellitus Type 2Pulsatile FlowArterial stiffnessCardiologyCognitive function; Endothelium function; Foot ulcer; Vascular health; Vascular stiffnessFemaleEndothelium VascularCognitive functionbusinessCardiology and Cardiovascular MedicineCardiovascular Diabetology
researchProduct

Variability in individual response to various doses of omeprazole. Implications for antiulcer therapy.

1994

This study was carried out in order to perform a combined prospective assessment of the individual pharmacodynamic response and of duodenal ulcer healing in patients treated with three different doses of omeprazole. Ninety-nine patients with endoscopically proven duodenal ulcers were subdivided into three parallel groups of 33 cases, who were randomly assigned to receive orally at 0800 hr, in single blind fashion, either 10 mg, 20 mg, or 40 mg of omeprazole. All of them underwent continuous intragastric pH monitoring both in basal conditions and on the fifth day of each dose regimen; ulcer healing was then assessed endoscopically after four weeks of treatment. All three doses of omeprazole …

Malemedicine.medical_specialtyTime FactorsPhysiologymedicine.medical_treatmentGastroenterologyGastric AcidBasal (phylogenetics)PharmacokineticsInternal medicineMedicineHumansSingle-Blind MethodOmeprazoleMonitoring PhysiologicChemotherapyWound HealingDose-Response Relationship Drugbusiness.industryGastroenterologyHepatologyHydrogen-Ion ConcentrationMiddle AgedRegimenmedicine.anatomical_structurePharmacodynamicsDuodenal UlcerDuodenumFemalebusinessIon-Selective ElectrodesOmeprazolemedicine.drugDigestive diseases and sciences
researchProduct

Effectiveness and safety of biologics in pediatric inflammatory boweldisease: Real-life data from the Sicilian Network

2019

Background: Biological therapies have modified the disease course of pediatric inflammatory bowel disease (IBD) and are routinely used in clinical practice. Our observational study aims to evaluate effectiveness and safety of biologics in IBD. Method: Clinical benefit and safety data of 93 children with IBD, receiving biologics (Infliximab – IFX, Adalimumab – ADA, Golimumab – GOL) from January 2013 to December 2017, were extracted from the cohort of the Sicilian Network of IBD. Results: Among 87 children aged 7–17 years (63 Crohn's disease [CD], 24 Ulcerative colitis [UC]), 101 out of 108 biologic treatments were considered. Evaluation of 74 biologic treatments in CD patients at 26, 52, 104…

Malemedicine.medical_specialtyYounger ageAdolescentBiologicEfficacyAnti-Inflammatory AgentsDiseaseInflammatory bowel diseaseInflammatory bowel disease03 medical and health sciences0302 clinical medicineCrohn DiseaseGastrointestinal AgentsInternal medicinemedicineHumansAdverse effectChildSicilyRetrospective StudiesBiological ProductsHepatologybusiness.industryGastroenterologyAdalimumabAntibodies MonoclonalBiologics; Child; Efficacy; Inflammatory bowel disease; Safetymedicine.diseaseUlcerative colitisReal life dataInfliximabTreatment Outcome030220 oncology & carcinogenesisCohort030211 gastroenterology & hepatologyObservational studyColitis UlcerativeFemaleSafetybusiness
researchProduct

Heat shock proteins and ulcerative colitis: The start of a new era?

2015

Malemedicine.medical_specialtybusiness.industryGastroenterologyMEDLINEmedicine.diseaseUlcerative colitisGastroenterologySurgeryHeat shock proteinInternal medicineHumansMedicineColitis UlcerativeFemaleHSP70 Heat-Shock ProteinsHSP90 Heat-Shock ProteinsIntestinal MucosaColitisbusinessPrecancerous ConditionsArab Journal of Gastroenterology
researchProduct

Effectiveness and Safety of Ustekinumab in Ulcerative Colitis: Real-world Evidence from the ENEIDA Registry

2021

Abstract Background and Aims The development programm UNIFI has shown promising results of ustekinumab in ulcerative colitis [UC] treatment which should be confirmed in clinical practice. We aimed to evaluate the durability, effectiveness, and safety of ustekinumab in UC in real life. Methods Patients included in the prospectively maintained ENEIDA registry, who received at least one intravenous dose of ustekinumab due to active UC [Partial Mayo Score [PMS]>2], were included. Clinical activity and effectiveness were defined based on PMS. Short-term response was assessed at Week 16. Results A total of 95 patients were included. At Week 16, 53% of patients had response [including 35% o…

Malemedicine.medical_specialtyustekinumabVedolizumab03 medical and health sciences0302 clinical medicineremissionColitis ulcerosaInternal medicineUstekinumabHumansMedicineProspective StudiesRegistriesInfusions IntravenousAdverse effectreal-world evidenceAcademicSubjects/MED00260ulcerative colitisTofacitinibresponsebiologybusiness.industryRemission InductionC-reactive proteinGastroenterologyGeneral MedicineMiddle Agedmedicine.diseaseUlcerative colitisDiscontinuation030220 oncology & carcinogenesisCohortbiology.proteindurabilityOriginal ArticleColitis UlcerativeFemaleMonoclonal antibodies030211 gastroenterology & hepatologyUstekinumabbusinessAnticossos monoclonalsmedicine.drug
researchProduct

Haemodynamic predictors of a penetrating atherosclerotic ulcer rupture using fluid-structure interaction analysis

2013

We present preliminary data on the flow-induced haemodynamic and structural loads exerted on a penetrating atherosclerotic aortic ulcer (PAU). Specifically, one-way fluid-structure interaction analysis was performed on the aortic model reconstructed from a 66-year-old male patient with a PAU that evolved into an intramural haematoma and rupture of the thoracic aorta. The results show that elevated blood pressure (117 mmHg) and low flow velocity at the aortic wall (0.15 m/s(2)) occurred in the region of the PAU. We also found a low value of time-averaged wall shear stress (1.24 N/m(2)) and a high value of the temporal oscillation in the wall shear stress (oscillatory shear index = 0.13) in t…

Malemedicine.medical_treatmentHemodynamicsAorta ThoracicMedicineThoracic aortaHematomamedicine.diagnostic_testEndovascular ProceduresModels CardiovascularSettore ING-IND/34 - Bioingegneria IndustrialeAnatomyTreatment OutcomeAtherosclerosiCardiologyWall shear streCardiology and Cardiovascular MedicineBrief CommunicationsBlood Flow VelocityHumanPulmonary and Respiratory Medicinemedicine.medical_specialtyAortographyAortic RuptureAortic DiseasesAortographyBlood Vessel Prosthesis ImplantationSettore ING-IND/14 - Progettazione Meccanica E Costruzione Di MacchinePenetrating atherosclerotic ulcerPenetrating atherosclerotic ulcerInternal medicinemedicine.arteryFluid-structure interactionShear stressHumansArterial PressureComputer SimulationHemodynamicAortic ruptureUlcerAgedEndovascular Procedurebusiness.industryHemodynamicsStentmedicine.diseaseAtherosclerosisAortic DiseaseBlood pressureRegional Blood FlowSurgeryStress MechanicalbusinessTomography X-Ray Computed
researchProduct

A nanomaterial-based breath test for distinguishing gastric cancer from benign gastric conditions

2013

Background: Upper digestive endoscopy with biopsy and histopathological evaluation of the biopsy material is the standard method for diagnosing gastric cancer (GC). However, this procedure may not be widely available for screening in the developing world, whereas in developed countries endoscopy is frequently used without major clinical gain. There is a high demand for a simple and non-invasive test for selecting the individuals at increased risk that should undergo the endoscopic examination. Here, we studied the feasibility of a nanomaterial-based breath test for identifying GC among patients with gastric complaints. Methods: Alveolar exhaled breath samples from 130 patients with gastric …

Malevolatile organic compoundCancer Researchmedicine.medical_specialtyPathologydiagnosisPilot Projects02 engineering and technologyGastroenterology03 medical and health sciences0302 clinical medicineStomach NeoplasmssensorInternal medicineBiopsymedicineHumansStomach Ulcerbreath analysisStage (cooking)Molecular DiagnosticsBreath testVolatile Organic Compoundsmedicine.diagnostic_testbiologybusiness.industrygastric cancerConfoundingCancerMiddle AgedHelicobacter pylori021001 nanoscience & nanotechnologybiology.organism_classificationmedicine.diseaseNanostructures3. Good healthEndoscopyClinical trialBreath TestsMolecular Diagnostic TechniquesOncology030220 oncology & carcinogenesisFemale0210 nano-technologybusinessBiomarkersBritish Journal of Cancer
researchProduct